Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2015 2
2016 7
2017 5
2018 7
2019 13
2020 14
2021 11
2022 12
2023 11
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Results by year

Filters applied: . Clear all
Page 1
Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.
Zhou C, Tang KJ, Cho BC, Liu B, Paz-Ares L, Cheng S, Kitazono S, Thiagarajan M, Goldman JW, Sabari JK, Sanborn RE, Mansfield AS, Hung JY, Boyer M, Popat S, Mourão Dias J, Felip E, Majem M, Gumus M, Kim SW, Ono A, Xie J, Bhattacharya A, Agrawal T, Shreeve SM, Knoblauch RE, Park K, Girard N; PAPILLON Investigators. Zhou C, et al. N Engl J Med. 2023 Nov 30;389(22):2039-2051. doi: 10.1056/NEJMoa2306441. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870976 Clinical Trial.
Cognitive impairment and chemotherapy: a brief overview.
Vitali M, Ripamonti CI, Roila F, Proto C, Signorelli D, Imbimbo M, Corrao G, Brissa A, Rosaria G, de Braud F, Garassino MC, Lo Russo G. Vitali M, et al. Among authors: proto c. Crit Rev Oncol Hematol. 2017 Oct;118:7-14. doi: 10.1016/j.critrevonc.2017.08.001. Epub 2017 Aug 14. Crit Rev Oncol Hematol. 2017. PMID: 28917271 Review.
Treatment of lung large cell neuroendocrine carcinoma.
Lo Russo G, Pusceddu S, Proto C, Macerelli M, Signorelli D, Vitali M, Ganzinelli M, Gallucci R, Zilembo N, Platania M, Buzzoni R, de Braud F, Garassino MC. Lo Russo G, et al. Among authors: proto c. Tumour Biol. 2016 Jun;37(6):7047-57. doi: 10.1007/s13277-016-5003-4. Epub 2016 Mar 4. Tumour Biol. 2016. PMID: 26943800 Review.
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
Viscardi G, Tralongo AC, Massari F, Lambertini M, Mollica V, Rizzo A, Comito F, Di Liello R, Alfieri S, Imbimbo M, Della Corte CM, Morgillo F, Simeon V, Lo Russo G, Proto C, Prelaj A, De Toma A, Galli G, Signorelli D, Ciardiello F, Remon J, Chaput N, Besse B, de Braud F, Garassino MC, Torri V, Cinquini M, Ferrara R. Viscardi G, et al. Among authors: proto c. Eur J Cancer. 2022 Dec;177:175-185. doi: 10.1016/j.ejca.2022.09.031. Epub 2022 Oct 5. Eur J Cancer. 2022. PMID: 36368251 Review.
Diagnosis and management of typical and atypical lung carcinoids.
Pusceddu S, Lo Russo G, Macerelli M, Proto C, Vitali M, Signorelli D, Ganzinelli M, Scanagatta P, Duranti L, Trama A, Buzzoni R, Pelosi G, Pastorino U, de Braud F, Garassino MC. Pusceddu S, et al. Among authors: proto c. Crit Rev Oncol Hematol. 2016 Apr;100:167-76. doi: 10.1016/j.critrevonc.2016.02.009. Epub 2016 Feb 18. Crit Rev Oncol Hematol. 2016. PMID: 26917456 Review.
New options and open issues in the management of unresectable stage III and in early-stage NSCLC: A report from an expert panel of Italian medical and radiation oncologists - INTERACTION group.
Catania C, Filippi AR, Sangalli C, Piperno G, Russano M, Greco C, Scotti V, Proto C, Bennati C, Di Pietro Paolo M, Platania A, Olmetto E, Agustoni F, Teodorani N, Agbaje V, Russo A. Catania C, et al. Among authors: proto c. Crit Rev Oncol Hematol. 2023 Oct;190:104108. doi: 10.1016/j.critrevonc.2023.104108. Epub 2023 Aug 24. Crit Rev Oncol Hematol. 2023. PMID: 37633350 Review.
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
Brambilla M, Beninato T, Piemontese A, Mazzeo L, Pircher CC, Manglaviti S, Ambrosini P, Signorelli D, Lorenzini D, Prelaj A, Ferrara R, Proto C, Lo Russo G, Pizzutilo EG, Ganzinelli M, Grande I, Capone I, Di Mauro RM, Conca E, Dumitrascu AD, Zanella C, Leporati R, Rota S, Garassino MC, Marchetti P, de Braud FM, Occhipinti M. Brambilla M, et al. Among authors: proto c. Clin Lung Cancer. 2023 Nov;24(7):631-640.e2. doi: 10.1016/j.cllc.2023.08.004. Epub 2023 Aug 23. Clin Lung Cancer. 2023. PMID: 37775370 Free article.
Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
Lo Russo G, Pusceddu S, Prinzi N, Imbimbo M, Proto C, Signorelli D, Vitali M, Ganzinelli M, Maccauro M, Buzzoni R, Seregni E, de Braud F, Garassino MC. Lo Russo G, et al. Among authors: proto c. Tumour Biol. 2016 Oct;37(10):12991-13003. doi: 10.1007/s13277-016-5258-9. Epub 2016 Jul 27. Tumour Biol. 2016. PMID: 27460087 Review.
Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
Prinzi N, Rossi RE, Proto C, Leuzzi G, Raimondi A, Torchio M, Milione M, Corti F, Colombo E, Prisciandaro M, Cascella T, Spreafico C, Beninato T, Coppa J, Lo Russo G, Di Bartolomeo M, de Braud F, Pusceddu S. Prinzi N, et al. Among authors: proto c. Clin Lung Cancer. 2021 May;22(3):161-169. doi: 10.1016/j.cllc.2020.12.004. Epub 2020 Dec 17. Clin Lung Cancer. 2021. PMID: 33618994 Review.
Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era.
Catania C, Piperno G, Russo A, Greco C, Agustoni F, Scotti V, Proto C, Sangalli C, Patani F, Santacaterina A, Di Pietro Paolo M, Agresti B, Filippi AR, Ramella S. Catania C, et al. Among authors: proto c. Crit Rev Oncol Hematol. 2022 Jun;174:103684. doi: 10.1016/j.critrevonc.2022.103684. Epub 2022 Apr 21. Crit Rev Oncol Hematol. 2022. PMID: 35462031 Review.
79 results